85 Angiosarcoma, a rare and aggressive cancer affecting soft tissues and organs, has seen a concerning rise in incidence over the past four decades, according to recent findings. This malignant tumour, which constitutes less than 2% of all soft tissue sarcomas, has been increasingly documented in older populations. Between 1975 and 2016, the annual incidence of angiosarcoma in the United States more than doubled, raising awareness of its evolving epidemiology and prognosis. The findings were published in the journal Medicine. This study, drawing data from the Surveillance, Epidemiology, and End Results (SEER) database, provides a detailed overview of the condition’s demographic and clinical characteristics. The results indicate a significant rise in cases among those aged 60 and above, with this group seeing the sharpest annual percentage increases. The incidence rose from 0.13 per 100,000 in 1975 to 0.33 per 100,000 by 2016, revealing the growing impact of this disease. Angiosarcoma is highly heterogeneous, developing across various sites, including the skin, soft tissue, breast, and liver. The diversity of its presentation adds to the difficulty in predicting outcomes, as tumour grade, location, and size significantly influence survival rates. For instance, patients with breast angiosarcoma demonstrate better survival outcomes, whereas liver angiosarcomas are linked to poorer prognoses. While the overall prognosis remains poor, advances in treatment strategies have modestly improved survival rates. The median survival time currently ranges from 30 to 50 months, with five-year survival rates varying from 10% to 50%, depending on the tumour’s characteristics and site. Surgery, when feasible, continues to be a cornerstone of treatment, particularly for localised cases. Other factors, such as younger age and smaller tumour size, also contribute to improved survival outcomes. To address the complexity of predicting patient prognosis, researchers have developed a new prognostic model known as a nomogram. This model integrates key variables, including age, sex, tumour grade, and surgical history, to provide a more personalised survival prediction. The tool has demonstrated greater accuracy than traditional staging systems, such as the American Joint Committee on Cancer’s classification models. With a concordance index of 0.74, the nomogram offers clinicians a valuable resource for tailoring treatment strategies to individual patients. The increasing prevalence of angiosarcoma, coupled with its often grim prognosis, underscores the need for heightened awareness and earlier detection. Improved diagnostic techniques and a deeper understanding of risk factors, such as exposure to radiation and certain chemicals, could play a pivotal role in curbing the disease’s rise. As the population continues to age, addressing the growing burden of angiosarcoma will require coordinated efforts in research, public health, and clinical practice.